Clinical trial
Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering…
NCT00263081 · Takeda, Industry · Terminated
Key facts
| NCT number | NCT00263081 |
|---|---|
| Title | Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia |
| Official title | A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 or Placebo When Co-administered With Current Lipid-lowering Therapy in Subjects With Homozygous Familial Hypercholesterolemia. |
| Lead sponsor | Takeda, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypercholesterolemia |
| Intervention type | Drug |
| Interventions | Lapaquistat acetate and current lipid-lowering treatment, Current lipid-lowering treatment |
| Enrollment | 44 |
| Start date | Nov 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Dec 7, 2005 |
| Last update posted | May 24, 2012 |
| Countries | Canada, France, Israel, Poland, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: